Clinuvel (ASX:CUV) share price pinches down after Israeli breakthrough

The Clinuvel (ASX: CUV) share price closed lower today after the company announced expansion into Israel. Here are the latest details.

| More on:
sad, unhappy medical worker, medical share price fall, drop, decrease,

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price closed 1.15% lower today at $21.54. The dip came after the company announced that its SCENESSE product had been added to Israel's 'National Health Basket' (NHB) of reimbursable services and products. 

Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of genetic and vascular disorders. 

The company's main product is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).

What's driving the Clinuvel share price?

Earlier today, Clinuvel announced that it had achieved a positive outcome in Israel regarding its SCENESSE treatment. The product, which is already available in the European Union and the United States, will now be commercially prescribed in Israel.

The company noted that Israel's healthcare costs amounted to 7.5% of GDP, and spending on pharmaceutical products equated to 13.1% of all healthcare. 

Clinuvel said while it was compulsory that Israeli residents were provided insurance under the National Health Insurance Law (enacted 1994), most residents also opted for voluntary health insurance options. This was in order to gain benefits including medications not covered by the standard package, and access to faster healthcare and a more comprehensive network of doctors. 

Management comments

Clinuvel's commercial affairs vice president Antonella Colucci welcomed the expansion into Israel, saying:

Our team has been working tirelessly to facilitate accelerated access to SCENESSE treatment for Israeli EPP patients.

We are establishing a foothold and infrastructure in Israel to enable treatment accessing a country where the risk of EPP burns and phototoxicity is high due to the light intensity and sun exposure. Israeli EPP patients have been at heightened risk for decades and had to learn to live a recluse life.

The Clinuvel share price has fallen more than 17% during the past 12 months. 

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Record Highs

The ASX 200 Index is on its way to another all-time high today. Here's why

These blue chip stocks are driving the index towards a new record today...

Read more »

Group of friends trading stocks on their phones. symbolising the 3 most traded ASX 200 shares today
Share Market News

3 ASX mining stocks topping the most-traded list in October

Chinese stimulus news and company announcements likely contributed to the higher trading activity.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Megaport, Pilbara Minerals, Vysarn, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »